Swimming the Catalan coast to raise funds for TRICALS

To raise funds for TRICALS, Daniel Rossinés has taken on an epic challenge. In 24 consecutive days he is swimming the entire Catalan coast: 400 km. He started in Portbou (Girona) on the 17th of September and will finish in Les Cases d’Alcanar (Tarragona).

Daniel Rossinés started to raise funds for ALS research in 2014 when he learned that his good friend was diagnosed with ALS. He then decided to combine his love for open water swimming with his skills in business management to organise fundraising challenges. For his next brave effort, the ‘Upside Down Challenge’, he swims along the Catalan coast from north to south. Other people have also joined him at several stages of his journey so far.

Besides raising money, this action also aims to raise more awareness about ALS. His initiative has already received a lot of media attention in Spain and is sponsored by former footballer and coach Juan Carlos Unzué, who announced last June that he suffers from ALS. The children of the sportsman have even accompanied Daniel Rossinés on one day of his swim.

At this moment, Daniel Rossinés has swum over 200 km and raised more than €48.000. The goal is to raise €200.000 – €1 for every swimming stroke. All the money raised will be managed by Fundación Luzón and goes towards research activities of TRICALS. We are very grateful for this courageous initiative and wish Daniel all the strength to face the second half of his journey ahead. We thank him, and everyone who donated or joined him in this challenge, for their support in our mission to speed up the development of new therapies for people living with ALS.

Donations can be made by clicking this link (in Spanish).

Updates of the project are regularly shared on the Upside Down Challenge Instagram account.


Share

Related news

The VALOR Study – A Clinical Trial for People Living with SOD1-ALS
The VALOR Study – A Clinical Trial for People Living with SOD1-ALS
Biogen is conducting a clinical trial to evaluate the safety and potential […]
CENTAUR phase 2 trial reveals promising results
CENTAUR phase 2 trial reveals promising results
New findings from the CENTAUR trial show that the drug ‘sodium phenylbutyrate–taurursodiol’ […]
Current developments in clinical trial design and conduct
Current developments in clinical trial design and conduct
Over 70 compounds have been evaluated by clinical studies, yet Riluzole is […]
Reforming clinical studies for ALS
Reforming clinical studies for ALS
In order to find new treatments for ALS, our current strategy for […]